Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Change in Account Payables (2022 - 2025)

Entrada Therapeutics has reported Change in Account Payables over the past 4 years, most recently at -$877000.0 for Q4 2025.

  • Quarterly results put Change in Account Payables at -$877000.0 for Q4 2025, down 130.82% from a year ago — trailing twelve months through Dec 2025 was -$1.8 million (down 281.53% YoY), and the annual figure for FY2025 was -$1.8 million, down 281.53%.
  • Change in Account Payables for Q4 2025 was -$877000.0 at Entrada Therapeutics, down from $1.3 million in the prior quarter.
  • Over the last five years, Change in Account Payables for TRDA hit a ceiling of $4.6 million in Q4 2022 and a floor of -$4.4 million in Q2 2023.
  • Median Change in Account Payables over the past 4 years was -$317500.0 (2024), compared with a mean of $104625.0.
  • Biggest five-year swings in Change in Account Payables: plummeted 384.42% in 2023 and later surged 516.88% in 2025.
  • Entrada Therapeutics' Change in Account Payables stood at $4.6 million in 2022, then plummeted by 47.62% to $2.4 million in 2023, then rose by 18.29% to $2.8 million in 2024, then crashed by 130.82% to -$877000.0 in 2025.
  • The last three reported values for Change in Account Payables were -$877000.0 (Q4 2025), $1.3 million (Q3 2025), and -$321000.0 (Q2 2025) per Business Quant data.